How much does elective cardioversion increase the risk of ischaemic stroke compared to the baseline risk in atrial fibrillation? A nationwide study.
Authors:
- Saga Itäinen-StrömbergSISaga Itäinen-Strömberg
- Mika LehtoMLMika Lehto
- Olli HalminenOHOlli Halminen
- Jari HaukkaJHJari Haukka
- Jukka PutaalaJPJukka Putaala
- Ossi LehtonenOLOssi Lehtonen
- Pirjo MustonenPMPirjo Mustonen
- Miika LinnaMLMiika Linna
- Juha HartikainenJHJuha Hartikainen
- Kari Eino Juhani AiraksinenKAKari Eino Juhani Airaksinen
- Konsta TeppoKTKonsta Teppo
- Aapo L AroAAAapo L Aro
Open Access
- 1 December 2025
- journal article
- research article
- Vol. 27 (12)
Abstract
Patients with atrial fibrillation (AF) undergoing cardioversion (CV) are exposed to increased risk of ischaemic stroke (IS), but the exact magnitude is unknown. We compared IS rates during the post-CV period with the long-term risk in AF patients using guideline-recommended anticoagulation therapy. This nationwide register-based study included all AF patients undergoing first-ever elective CV between 2012 and 2018 in Finland. Breakpoint analysis identified a cut-off point in the IS rate at 2 weeks after CV. Follow-up was split into two intervals: the immediate 2-week post-CV period and the subsequent period up to 360 days. Stroke rates were calculated, and incidence rate ratios were estimated with Poisson regression. Interactions between the two follow-up periods and conventional IS risk factors as well as anticoagulation treatment were assessed. A total of 9625 patients were identified (mean age 67.7 ± 9.9 years, 61.2% men, mean CHA2DS2-VA score 2.2 ± 1.4). Warfarin was used in 6245 (64.9%) and non-vitamin K oral anticoagulants in 3380 (35.1%) patients. Overall, 92 (1.0%) patients experienced IS during the year after CV. Breakpoint analysis and survival plot displayed a higher incidence of IS within the first 2 weeks after CV, stabilizing thereafter to a consistent level. The adjusted IS rate during the first 2 weeks was 7.5-fold (95% confidence interval: 4.8-11.8) compared to the subsequent IS rate. This excess risk was independent of the anticoagulation type or conventional stroke risk factors. The rate of IS was roughly seven times higher during the first 2 weeks after elective CV compared to the subsequent 360 days.Keywords
This publication has 24 references indexed in Scilit:
- Strokes after cardioversion of atrial fibrillation — The FibStroke studyInternational Journal of Cardiology, 2016
- Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillationEuropean Heart Journal, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Thromboembolic Complications After Cardioversion of Acute Atrial FibrillationJACC, 2013
- Quality of the Finnish Hospital Discharge Register: A systematic reviewScandinavian Journal of Public Health, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversionJACC, 2002
- Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial FibrillationNew England Journal of Medicine, 2001
- Timing of thromboembolic events after electical cardioversion of atrial fibrillation or flutter: a retrospective analysisThe American Journal of Cardiology, 1998
- Cardioversion of atrial fibrillationPostgraduate Medical Journal, 1995